CWM
CATX icon

Catamount Wealth Management’s Perspective Therapeutics CATX Stock Holding History

Catamount Wealth Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-500
Closed -$2K – 184
2018
Q1 		$2K Hold
500
– – ﹤0.01% 172
2017
Q4 		$2K Hold
500
– – ﹤0.01% 177
2017
Q3 		$3K Buy
500
+150
+43% +$843 ﹤0.01% 164
2017
Q2 		$2K Buy
+350
New +$1.98K ﹤0.01% 158

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CWM
Cahaba Wealth Management Atlanta, Georgia $1.66B AUM 17.04% 1-Year Est. Return
IFS
Ifrah Financial Services Little Rock, Arkansas $409M AUM 28.15% 1-Year Est. Return

Catamount Wealth Management's CATX Position: Q2 2018 in Review

Catamount Wealth Management sold out of Perspective Therapeutics (CATX) in Q2 2018, closing a stake of 500 shares — an estimated $2K sold.

Catamount Wealth Management first reported a position in CATX in Q2 2017 and held it in 4 quarters. The position peaked at $3K in Q3 2017. 30 funds tracked by Wall St. Rank hold CATX as of Q2 2018.

  • Catamount Wealth Management reported no remaining Perspective Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Catamount Wealth Management sold 500 Perspective Therapeutics shares in Q2 2018, an estimated $2K.
  • Catamount Wealth Management first reported a position in Perspective Therapeutics in Q2 2017 and held it in 4 quarters.
  • Catamount Wealth Management's Perspective Therapeutics position peaked at $3K in Q3 2017.
  • 30 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2018.

Based on Catamount Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.